Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s share price was up 0.6% on Friday . The stock traded as high as $0.90 and last traded at $0.89. Approximately 13,050 shares were traded during trading, a decline of 7% from the average daily volume of 14,034 shares. The stock had previously closed at $0.88.
Humacyte Stock Performance
The firm’s 50 day moving average is $1.34 and its two-hundred day moving average is $1.62.
About Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
- Five stocks we like better than Humacyte
- What Is WallStreetBets and What Stocks Are They Targeting?
- How to Build the Ultimate Everything ETF Portfolio
- How to Use Stock Screeners to Find Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
